BeOne Medicines raises 2026 revenue guidance to $6.9 billion-$7 billion
ONC•BeOne Medicines raised its 2026 revenue guidance to $6.9 billion-$7 billion from $6.6 billion-$6.8 billion. Third-quarter revenue rose 34% to $1.89 billion, including 34% growth in BRUKINSA sales to $1.39 billion.
1. Raised outlook
BeOne Medicines raised its 2026 revenue forecast to $6.9 billion-$7 billion from $6.6 billion-$6.8 billion. GAAP operating income guidance increased to $1.2 billion-$1.3 billion from $1 billion-$1.1 billion, while non-GAAP operating income is now projected at $1.9 billion-$2 billion, up from $1.7 billion-$1.8 billion.
2. Quarterly revenue
Third-quarter revenue rose 34% to $1.89 billion, with BRUKINSA sales growing 34% to $1.39 billion. The outlook includes an expected fourth-quarter reversal of certain valuation allowances, resulting in a material tax benefit.
